Background: Diabetes mellitus (DM) affects more than 537 million adults worldwide and is increasingly prevalent among patients presenting with urolithiasis, constituting 10–15% or more of the extracorporeal shock wave lithotripsy (ESWL) caseload in many centres. The metabolic derangements of diabetes — particularly insulin resistance and impaired renal ammoniagenesis — fundamentally alter stone composition, operative risk, and post-procedural recovery in ways that distinguish the diabetic patient from the general stone population.

Objectives: This article synthesizes the available evidence on three clinically critical dimensions of ESWL in the diabetic patient: (1) the nature and implications of stone disease in diabetes, with emphasis on the predominance of radiolucent uric acid stones; (2) the diabetic patient’s unique complication profile — encompassing infection risk, nephropathy-related renal vulnerability, and autonomic neuropathy; and (3) the contested hypothesis that ESWL may induce or exacerbate diabetes through subclinical pancreatic injury.

Methods: A structured narrative review was conducted incorporating landmark studies, population-based cohort analyses, and major guideline statements — including the 2025 American Urological Association (AUA) Surgical Management of Kidney and Ureteral Stones Guideline. Key data sources include a series of 2,464 calculi demonstrating uric acid stone predominance in Type 2 DM (Daudon et al., JASN 2006), a retrospective cohort of 1,838 ESWL treatments identifying diabetes as an independent predictor of post-procedural complications (Lildal et al., Scand J Urol 2017), and multiple long-term studies evaluating ESWL as a potential risk factor for new-onset diabetes, including the Mayo Clinic 19-year case-control study (Krambeck et al., J Urol 2006) and the Ontario population-based cohort of all ESWL and ureteroscopy treatments between 1994 and 2014 (PMID: 30358066).

Results: Uric acid stones constitute 35.7% of calculi in Type 2 diabetic patients compared to 11.3% in non-diabetic stone formers — a near three-fold enrichment with direct implications for ESWL targeting, as these stones are radiolucent on fluoroscopy and require ultrasound guidance. Non-contrast CT Hounsfield unit measurement serves a dual function, predicting both stone fragility (uric acid stones typically < 500 HU) and composition. Urine culture — not urinalysis alone — is mandated by the 2025 AUA Guideline for all diabetic patients prior to ESWL due to elevated infectious risk; diabetes was confirmed as an independent predictor of post-ESWL complications, with infection as the primary complication type. Diabetic nephropathy increases renal parenchymal vulnerability to shock wave injury; patients with eGFR < 45 mL/min/1.73m² should be considered for ureteroscopy. The ESWL–diabetes causation hypothesis generated significant concern following the Krambeck Mayo Clinic study (OR ≈ 3.75 for new-onset DM at 19 years); however, the largest and most rigorously controlled population-based studies — including the Ontario cohort and Rochester Epidemiologic Project — found no elevated DM risk after appropriate covariate adjustment, and the NHANES-matched study of 1,869 patients demonstrated statistically identical DM incidence between ESWL-treated and control populations.

Conclusions: ESWL remains a safe and appropriate treatment modality for carefully selected diabetic stone patients, but requires a significantly more deliberate pre-procedural assessment than for the general stone population. Mandatory urine culture, glycaemic status evaluation, renal function assessment, stone composition characterisation via non-contrast CT, and ultrasound guidance availability are essential prerequisites. Modern ESWL does not carry a proven risk of inducing new-onset diabetes; however, minimising cumulative high-energy sessions is a reasonable precaution, particularly for left-sided stones where pancreatic proximity is greatest. A practical evidence-based clinical protocol for pre-treatment assessment, intraoperative modifications, and post-procedural surveillance is presented to guide safe ESWL practice in the diabetic patient.